Keith H Nuechterlein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6309910/publications.pdf

Version: 2024-02-01

17440 13379 18,265 179 63 130 citations h-index g-index papers

180 180 180 11416 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning. Psychological Medicine, 2022, 52, 1517-1526.	4.5	19
2	Cognitive heterogeneity in first-episode psychosis and its relationship with premorbid developmental adjustment. Psychological Medicine, 2022, 52, 3885-3894.	4.5	5
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
4	The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder. Schizophrenia Research, 2022, 243, 86-97.	2.0	8
5	Computerâ€aided learning for managing stress: A feasibility trial with clinical high risk adolescents and young adults. Microbial Biotechnology, 2021, 15, 471-479.	1.7	1
6	Personnel time required for supported employment and education services for individuals in a recent $\hat{a} \in O$ onset psychosis treatment program. Microbial Biotechnology, 2021, 15, 402-405.	1.7	5
7	Changes in inflammation are related to depression and amount of aerobic exercise in first episode schizophrenia. Microbial Biotechnology, 2021, 15, 213-216.	1.7	11
8	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. Schizophrenia Research, 2021, 231, 179-188.	2.0	6
9	Awareness of illness is associated with better social and nonsocial cognition in recent-onset schizophrenia. Schizophrenia Research, 2021, 231, 51-53.	2.0	1
10	Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia. American Journal of Psychiatry, 2021, 178, 838-847.	7.2	80
11	Linguistic and neurocognitive correlates of probabilistic classification learning in schizophrenia. Schizophrenia Research: Cognition, 2021, 26, 100209.	1.3	3
12	The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry, 2021, 20, 4-33.	10.4	153
13	Confident memory errors and disrupted reality testing in early psychosis. Schizophrenia Research, 2021, 238, 170-177.	2.0	4
14	Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training. Psychological Medicine, 2020, 50, 20-28.	4.5	42
15	Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. Microbial Biotechnology, 2020, 14, 106-114.	1.7	17
16	Evidence of shared familial factors influencing neurocognitive endophenotypes in adult- and childhood-onset schizophrenia. Psychological Medicine, 2020, 50, 1672-1679.	4.5	8
17	S81. METAMEMORY IMPAIRMENT ACROSS THE PSYCHOSIS TRAJECTORY: ASSOCIATIONS WITH SYMPTOM SEVERITY. Schizophrenia Bulletin, 2020, 46, S65-S65.	4.3	O
18	Early Visual Processing Is Associated With Social Cognitive Performance in Recent-Onset Schizophrenia. Frontiers in Psychiatry, 2020, 11, 823.	2.6	13

#	Article	IF	CITATIONS
19	Heritability of acoustic startle magnitude and latency from the consortium on the genetics of schizophrenia. Schizophrenia Research, 2020, 224, 33-39.	2.0	3
20	Structural and Functional Connectivity of Visual Cortex in Schizophrenia and Bipolar Disorder: A Graph-Theoretic Analysis. Schizophrenia Bulletin Open, 2020, 1, sgaa056.	1.7	10
21	Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients. Schizophrenia Research, 2020, 222, 397-410.	2.0	10
22	The effects of age and sex on cognitive impairment in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS) study. PLoS ONE, 2020, 15, e0232855.	2.5	21
23	Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery. Schizophrenia Research, 2020, 218, 85-92.	2.0	13
24	Associations between physiological responses to social-evaluative stress and daily functioning in first-episode schizophrenia. Schizophrenia Research, 2020, 218, 233-239.	2.0	5
25	Relationship of poor insight to neurocognition, social cognition, and psychiatric symptoms in schizophrenia: A meta-analysis. Schizophrenia Research, 2020, 220, 164-171.	2.0	21
26	Title is missing!. , 2020, 15, e0232855.		0
27	Title is missing!. , 2020, 15, e0232855.		0
28	Title is missing!. , 2020, 15, e0232855.		0
29	Title is missing!. , 2020, 15, e0232855.		0
30	Social vs. non-social measures of learning potential for predicting community functioning across phase of illness in schizophrenia. Schizophrenia Research, 2019, 204, 104-110.	2.0	6
31	Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. JAMA Psychiatry, 2019, 76, 1274.	11.0	78
32	F39. LEPTIN-BINDING PROTEIN LEVELS ARE ASSOCIATED WITH COGNITIVE FUNCTIONING EARLY IN THE COURSE OF SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S270-S270.	4.3	1
33	Affective prosody and facial emotion recognition in first-episode schizophrenia: Associations with functioning & Schizophrenia Research: Cognition, 2019, 18, 100153.	1.3	11
34	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. Schizophrenia Research, 2019, 208, 182-189.	2.0	22
35	fMRI evidence of aberrant neural adaptation for objects in schizophrenia and bipolar disorder. Human Brain Mapping, 2019, 40, 1608-1617.	3.6	28
36	Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophrenia Research, 2019, 206, 291-299.	2.0	13

3

#	Article	IF	Citations
37	Cognitive remediation can improve negative symptoms and social functioning in first-episode schizophrenia: A randomized controlled trial. Schizophrenia Research, 2019, 203, 24-31.	2.0	45
38	Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues in Clinical Neuroscience, 2019, 21, 239-248.	3.7	117
39	Temporal lobe thickness and verbal memory in first-degree relatives of individuals with schizophrenia. Schizophrenia Research, 2018, 199, 221-225.	2.0	10
40	Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 454-462.	1.5	18
41	Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophrenia Research, 2018, 198, 6-15.	2.0	52
42	Episodic Memory for Dynamic Social Interaction Across Phase of Illness in Schizophrenia. Schizophrenia Bulletin, 2018, 44, 620-630.	4.3	6
43	Clinical and Cognitive Significance of Auditory Sensory Processing Deficits in Schizophrenia. American Journal of Psychiatry, 2018, 175, 275-283.	7.2	56
44	Family burden predicts functional outcome in the early course of schizophrenia beyond psychiatric symptoms and baseline functioning. Schizophrenia Research, 2018, 202, 328-332.	2.0	5
45	A direct examination of the cognitive underpinnings of multitasking abilities: A first study examining schizophrenia. Psychiatry Research, 2018, 268, 288-296.	3.3	7
46	Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2017, 43, sbw115.	4.3	270
47	Expressed emotion and the escalation of depressive symptoms in individuals with recentâ€onset schizophrenia. Microbial Biotechnology, 2017, 11, 351-353.	1.7	2
48	The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study. Schizophrenia Research, 2017, 185, 148-153.	2.0	19
49	Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. Schizophrenia Research, 2017, 185, 137-143.	2.0	31
50	The Pioneering Contributions of Irving Gottesman. Clinical Psychological Science, 2017, 5, 424-426.	4.0	0
51	Assessing neural tuning for object perception in schizophrenia and bipolar disorder with multivariate pattern analysis of fMRI data. Neurolmage: Clinical, 2017, 16, 491-497.	2.7	18
52	SA96. Schizophrenia and Schizophrenia-Spectrum Disorders in the First-Degree Relatives of Children and Adults With Schizophrenia: The UCLA Family Study. Schizophrenia Bulletin, 2017, 43, S147-S147.	4.3	1
53	SU78. Intracortical Myelination Within the Frontal Lobe as a Potential Biomarker for Therapeutic Effectiveness in Antipsychotics Using MRI With Selective Myelin-Lipid Suppression at 1.5 and 3 T. Schizophrenia Bulletin, 2017, 43, S189-S189.	4.3	0
54	Abnormal Ventral and Dorsal Attention Network Activity during Single and Dual Target Detection in Schizophrenia. Frontiers in Psychology, 2016, 7, 323.	2.1	29

#	Article	IF	CITATIONS
55	Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study. Schizophrenia Bulletin, 2016, 42, S44-S52.	4.3	72
56	Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processing. Schizophrenia Research, 2016, 176, 467-472.	2.0	48
57	Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophrenia Research, 2016, 170, 30-40.	2.0	65
58	Cognitive Assessment Interview (CAI): Validity as a co-primary measure of cognition across phases of schizophrenia. Schizophrenia Research, 2016, 172, 137-142.	2.0	12
59	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. Schizophrenia Research, 2016, 172, 106-113.	2.0	20
60	Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. American Journal of Psychiatry, 2016, 173, 385-391.	7.2	42
61	Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients. Journal of the International Neuropsychological Society, 2015, 21, 868-879.	1.8	27
62	Factors predicting work outcome in Japanese patients with schizophrenia: role of multiple functioning levels. Schizophrenia Research: Cognition, 2015, 2, 105-112.	1.3	15
63	The RAISE Connection Program for Early Psychosis. Journal of Nervous and Mental Disease, 2015, 203, 365-371.	1.0	30
64	Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research, 2015, 163, 38-46.	2.0	62
65	Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophrenia Research, 2015, 163, 17-23.	2.0	37
66	Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophrenia Research, 2015, 163, 63-72.	2.0	154
67	Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophrenia Research, 2015, 163, 73-79.	2.0	52
68	Hippocampal dysfunction during declarative memory encoding in schizophrenia and effects of genetic liability. Schizophrenia Research, 2015, 161, 357-366.	2.0	31
69	Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8years later. Schizophrenia Research, 2015, 161, 407-413.	2.0	121
70	California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: Comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research, 2015, 163, 32-37.	2.0	12
71	Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) Study: The moderating role of smoking status and antipsychotic medications. Schizophrenia Research, 2015, 163, 24-31.	2.0	26
72	The utility of P300 as a schizophrenia endophenotype and predictive biomarker: Clinical and socio-demographic modulators in COGS-2. Schizophrenia Research, 2015, 163, 53-62.	2.0	87

#	Article	IF	CITATIONS
73	Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. JAMA Psychiatry, 2015, 72, 822.	11.0	205
74	Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophrenia Research, 2015, 163, 47-52.	2.0	16
75	Contributions of Feature Binding During Encoding and Functional Connectivity of the Medial Temporal Lobe Structures to Episodic Memory Deficits Across the Prodromal and First-Episode Phases of Schizophrenia. Clinical Psychological Science, 2015, 3, 159-174.	4.0	21
76	Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches. American Journal of Psychiatric Rehabilitation, 2014, 17, 225-253.	0.7	46
77	Comparison of the Heritability of Schizophrenia and Endophenotypes in the COGS-1 Family Study. Schizophrenia Bulletin, 2014, 40, 1404-1411.	4.3	34
78	The MATRICS Consensus Cognitive Battery: What We Know 6 Years Later. American Journal of Psychiatry, 2014, 171, 1151-1154.	7.2	41
79	Social cognition and functional outcome in schizophrenia: The moderating role of cardiac vagal tone Journal of Abnormal Psychology, 2014, 123, 764-770.	1.9	9
80	A novel, online social cognitive training program for young adults with schizophrenia: A pilot study. Schizophrenia Research: Cognition, 2014, 1 , e11-e19.	1.3	93
81	Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophrenia Research, 2014, 152, 503-512.	2.0	91
82	The Relationship of Attitudinal Beliefs to Negative Symptoms, Neurocognition, and Daily Functioning in Recent-Onset Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1308-1318.	4.3	60
83	The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia. Schizophrenia Research, 2014, 159, 95-100.	2.0	13
84	Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery. Schizophrenia Research, 2014, 159, 182-187.	2.0	18
85	The early longitudinal course of cognitive deficits in schizophrenia. Journal of Clinical Psychiatry, 2014, 75 Suppl 2, 25-9.	2.2	37
86	Statistical shape analysis of the corpus callosum in Schizophrenia. Neurolmage, 2013, 64, 547-559.	4.2	38
87	Genome-Wide Linkage Analyses of 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. American Journal of Psychiatry, 2013, 170, 521-532.	7.2	114
88	Managing disclosure following recentâ€onset psychosis: utilizing the <scp>I</scp> ndividual <scp>P</scp> lacement and <scp>S</scp> upport model. Microbial Biotechnology, 2013, 7, 338-344.	1.7	17
89	The puzzle of schizophrenia: Tracking the core role of cognitive deficits. Development and Psychopathology, 2012, 24, 529-536.	2.3	35
90	Social Cognition in Schizophrenia, Part 2: 12-Month Stability and Prediction of Functional Outcome in First-Episode Patients. Schizophrenia Bulletin, 2012, 38, 865-872.	4.3	248

#	Article	IF	Citations
91	The Cultural Adaptability of Intermediate Measures of Functional Outcome in Schizophrenia*. Schizophrenia Bulletin, 2012, 38, 630-641.	4.3	23
92	Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia. Focus (American Psychiatric Publishing), 2012, 10, 231-238.	0.8	1
93	Social Cognition in Schizophrenia, Part 1: Performance Across Phase of Illness. Schizophrenia Bulletin, 2012, 38, 854-864.	4.3	354
94	Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophrenia Research, 2012, 140, 122-128.	2.0	70
95	Disease and genetic contributions toward local tissue volume disturbances in schizophrenia: A tensorâ€based morphometry study. Human Brain Mapping, 2012, 33, 2081-2091.	3.6	13
96	Relationships between perceptions of the family environment and of negative life events in recent-onset schizophrenia patients. Schizophrenia Research, 2011, 127, 266-267.	2.0	4
97	The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study. Schizophrenia Research, 2011, 126, 124-131.	2.0	204
98	Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophrenia Research, 2011, 132, 18-23.	2.0	88
99	Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory. Schizophrenia Research, 2011, 132, 35-41.	2.0	85
100	Mean diffusivity and fractional anisotropy as indicators of disease and genetic liability to schizophrenia. Journal of Psychiatric Research, 2011, 45, 980-988.	3.1	121
101	The attentional blink in schizophrenia: Isolating the perception/attention interface. Journal of Psychiatric Research, 2011, 45, 1346-1351.	3.1	20
102	Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia. American Journal of Psychiatry, 2011, 168, 286-292.	7.2	106
103	Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. American Journal of Psychiatry, 2011, 168, 930-946.	7.2	241
104	Neurocognitive Predictors of Work Outcome in Recent-Onset Schizophrenia. Schizophrenia Bulletin, 2011, 37, S33-S40.	4.3	256
105	Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia Psychological Assessment, 2011, 23, 245-261.	1.5	45
106	The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research, 2010, 121, 24-31.	2.0	76
107	Psychophysiological prodromal signs of schizophrenic relapse: A pilot study. Schizophrenia Research, 2010, 123, 64-67.	2.0	17
108	The contributions of disease and genetic factors towards regional cortical thinning in schizophrenia: The UCLA family study. Schizophrenia Research, 2010, 123, 116-125.	2.0	33

#	Article	IF	Citations
109	Schizophrenia as a Cognitive Disorder: Recent Approaches to Identifying its Core Cognitive Components to Aid Treatment Development., 2010,, 267-282.		O
110	Latest developments in the matrics process. Psychiatry, 2010, 7, 49-52.	0.3	7
111	Enhancing work functioning in early psychosis. , 2009, , 331-348.		1
112	Development and evaluation of a health promotion group for individuals with severe psychiatric disabilities Psychiatric Rehabilitation Journal, 2009, 33, 56-59.	1.1	11
113	Development of a measure of relationship perception in schizophrenia. Psychiatry Research, 2009, 166, 54-62.	3.3	81
114	Emotional intelligence in schizophrenia. Schizophrenia Research, 2009, 107, 61-68.	2.0	102
115	Commentary on O'Halloran et al. Schizophrenia Research, 2009, 107, 327-329.	2.0	2
116	Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis. Schizophrenia Research, 2009, 113, 189-199.	2.0	462
117	In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophrenia Research, 2009, 113, 322-331.	2.0	80
118	CNTRICS Final Task Selection: Control of Attention. Schizophrenia Bulletin, 2009, 35, 182-196.	4.3	84
119	Remember and know judgments during recognition in chronic schizophrenia. Schizophrenia Research, 2008, 100, 181-190.	2.0	49
120	The validity of Psychosis Proneness Scales as vulnerability indicators in recent-onset schizophrenia patients. Schizophrenia Research, 2008, 100, 224-236.	2.0	50
121	Stability of visual masking performance in recent-onset schizophrenia: An 18-month longitudinal study. Schizophrenia Research, 2008, 103, 266-274.	2.0	14
122	Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry, 2008, 64, 4-10.	1.3	172
123	Executive Functioning Component Mechanisms and Schizophrenia. Biological Psychiatry, 2008, 64, 26-33.	1.3	137
124	The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. American Journal of Psychiatry, 2008, 165, 203-213.	7.2	1,863
125	The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization. American Journal of Psychiatry, 2008, 165, 214-220.	7.2	593
126	Individual placement and support for individuals with recent-onset schizophrenia: Integrating supported education and supported employment Psychiatric Rehabilitation Journal, 2008, 31, 340-349.	1.1	188

#	Article	IF	Citations
127	Impaired implicit learning in schizophrenia Neuropsychology, 2008, 22, 606-617.	1.3	69
128	Selective corticostriatal dysfunction in schizophrenia: Examination of motor and cognitive skill learning Neuropsychology, 2008, 22, 100-109.	1.3	65
129	Initial Heritability Analyses of Endophenotypic Measures for Schizophrenia. Archives of General Psychiatry, 2007, 64, 1242.	12.3	351
130	Neurocognitive performance and functional disability in the psychosis prodrome. Schizophrenia Research, 2006, 84, 100-111.	2.0	232
131	Classifying episodes in schizophrenia and bipolar disorder: Criteria for relapse and remission applied to recent-onset samples. Psychiatry Research, 2006, 144, 153-166.	3.3	45
132	Translating basic attentional paradigms to schizophrenia research: Reconsidering the nature of the deficits. Development and Psychopathology, 2006, 18, 831-51.	2.3	27
133	The Consortium on the Genetics of Schizophrenia: Neurocognitive Endophenotypes. Schizophrenia Bulletin, 2006, 33, 49-68.	4.3	332
134	Social Perception as a Mediator of the Influence of Early Visual Processing on Functional Status in Schizophrenia. American Journal of Psychiatry, 2006, 163, 448-454.	7.2	296
135	Do Recent-Onset Schizophrenia Patients Experience a "Social Network Crisis�. Psychiatry (New York), 2006, 69, 115-129.	0.7	81
136	Distinguishing Separable Domains of Cognition in Human and Animal Studies: What Separations Are Optimal for Targeting Interventions? A Summary of Recommendations From Breakout Group 2 at the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference. Schizophrenia Bulletin, 2005, 31, 870-874.	4.3	50
137	Schizophrenia patients demonstrate a distinctive pattern of decision-making impairment on the Iowa Gambling Task. Schizophrenia Research, 2005, 72, 215-224.	2.0	207
138	Maintenance and manipulation of information in schizophrenia: further evidence for impairment in the central executive component of working memory. Schizophrenia Research, 2004, 68, 173-187.	2.0	91
139	Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 2004, 56, 301-307.	1.3	818
140	NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophrenia Research, 2004, 72, 11-19.	2.0	106
141	The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophrenia Research, 2004, 72, 1-3.	2.0	242
142	Identification of separable cognitive factors in schizophrenia. Schizophrenia Research, 2004, 72, 29-39.	2.0	1,086
143	Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biological Psychiatry, 2003, 53, 412-421.	1.3	115
144	A Prospective Study of Childhood Neurocognitive Functioning in Schizophrenic Patients and Their Siblings. American Journal of Psychiatry, 2003, 160, 2060-2062.	7.2	186

#	Article	IF	CITATIONS
145	Neurocognitive Impairments in Nonpsychotic Parents of Children With Schizophrenia and Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry, 2002, 59, 1053.	12.3	74
146	Neurocognitive functioning and schizophrenia spectrum disorders can be independent expressions of familial liability for schizophrenia in community control children: the UCLA family study. Schizophrenia Research, 2002, 54, 111-120.	2.0	18
147	The structure of schizotypy: relationships between neurocognitive and personality disorder features in relatives of schizophrenic patients in the UCLA Family Study. Schizophrenia Research, 2002, 54, 121-130.	2.0	62
148	The temporal stability of electrodermal variables over a one-year period in patients with recent-onset schizophrenia and in normal subjects. Psychophysiology, 2002, 39, 124-132.	2.4	35
149	Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia. American Journal of Psychiatry, 2001, 158, 1835-1842.	7.2	215
150	Family Transactions and Relapse in Bipolar Disorder*. Family Process, 2001, 40, 5-14.	2.6	47
151	Schizophrenia and Schizophrenia-Spectrum Personality Disorders in the First-Degree Relatives of Children With Schizophrenia. Archives of General Psychiatry, 2001, 58, 581.	12.3	180
152	Attention in HIV-infected children: Results from the Hemophilia Growth and Development Study. Journal of the International Neuropsychological Society, 2000, 6, 443-454.	1.8	28
153	Neurocognitive Vulnerability, Interpersonal Criticism, and the Emergence of Unusual Thinking by Schizophrenic Patients During Family Transactions. Archives of General Psychiatry, 2000, 57, 1174.	12.3	32
154	Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Research, 2000, 97, 129-135.	3.3	315
155	The factor structure of schizophrenia spectrum personality disorders: signs and symptoms in relatives of psychotic patients from the UCLA family members study. Psychiatry Research, 1999, 87, 137-146.	3.3	25
156	A longitudinal analysis of eye tracking dysfunction and attention in recent-onset schizophrenia. Psychophysiology, 1998, 35, 443-451.	2.4	20
157	Depressive Symptoms in the Early Course of Schizophrenia: Relationship to Familial Psychiatric Illness. American Journal of Psychiatry, 1997, 154, 1551-1556.	7.2	42
158	Reduced attention-related negative potentials in schizophrenic adults. Psychophysiology, 1994, 31, 272-281.	2.4	38
159	Intrafamilial relationships and the course of schizophrenia. Acta Psychiatrica Scandinavica, 1994, 90, 60-66.	4.5	18
160	Informationâ€processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. Acta Psychiatrica Scandinavica, 1994, 90, 71-79.	4.5	172
161	Developmental Processes in Schizophrenic Disorders: Longitudinal Studies of Vulnerability and Stress. Schizophrenia Bulletin, 1992, 18, 387-425.	4.3	460
162	Life Events and Schizophrenic Relapse after Withdrawal of Medication. British Journal of Psychiatry, 1992, 161, 615-620.	2.8	56

#	Article	IF	CITATIONS
163	Stress-Indicative Patterns of Non-Verbal Behaviour Their Role in Family Interaction. British Journal of Psychiatry, 1992, 161, 103-113.	2.8	8
164	Paths to Relapse: Possible Transactional Processes Connecting Patient Illness Onset, Expressed Emotion, and Psychotic Relapse. British Journal of Psychiatry, 1992, 161, 88-96.	2.8	62
165	Family Interaction Versus Individual Psychopathology. British Journal of Psychiatry, 1992, 161, 97-102.	2.8	25
166	Interrater reliability of the structured clinical interview for DSM-III-R, Axis II: Schizophrenia spectrum and affective spectrum disorders. Psychiatry Research, 1991, 39, 55-63.	3.3	48
167	Neuropsychological vulnerability or episode factors in schizophrenia?. Behavioral and Brain Sciences, 1991, 14, 37-38.	0.7	9
168	Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission Tomography. British Journal of Psychiatry, 1990, 156, 216-227.	2.8	297
169	Can Communication Deviance Be Measured in a Family Problem-Solving Interaction?. Family Process, 1990, 29, 213-226.	2.6	20
170	Patterns of Expressed Emotion and Patient Coping Styles that Characterise the Families of Recent Onset Schizophrenics. British Journal of Psychiatry, 1989, 155, 107-111.	2.8	35
171	Is Expressed Emotion an Index of a Transactional Process? I. Parents' Affective Style. Family Process, 1989, 28, 153-167.	2.6	102
172	Is Expressed Emotion an Index of a Transactional Process? II. Patient's Coping Style. Family Process, 1989, 28, 169-181.	2.6	103
173	The Relationship of Symptomatology and Medication to Electrodermal Activity in Schizophrenia. Psychophysiology, 1989, 26, 148-157.	2.4	61
174	A prospective study of stressful life events and schizophrenic relapse Journal of Abnormal Psychology, 1989, 98, 407-411.	1.9	168
175	Prodromal signs and symptoms of schizophrenic relapse Journal of Abnormal Psychology, 1988, 97, 405-412.	1.9	118
176	Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children Journal of Abnormal Psychology, 1983, 92, 4-28.	1.9	321
177	Schizophrenic information-processing deficit: What type or level of processing is disordered?. Behavioral and Brain Sciences, 1982, 5, 609-610.	0.7	2
178	Reaction Time and Attention in Schizophrenia: A Critical Evaluation of the Data and Theories*. Schizophrenia Bulletin, 1977, 3, 373-428.	4.3	302
179	Neurocognitive vulnerability factors for schizophrenia: Convergence across genetic risk studies and longitudinal trait–state studies , 0, , 299-327.		26